跳轉至內容
Merck
全部照片(1)

重要文件

240R-1

Sigma-Aldrich

COX-2 (SP21) Rabbit Monoclonal Antibody

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

rabbit

品質等級

100
500

共軛

unconjugated

抗體表格

culture supernatant

抗體產品種類

primary antibodies

無性繁殖

SP21, monoclonal

描述

For In Vitro Diagnostic Use in Select Regions (See Chart)

形狀

buffered aqueous solution

物種活性

human

包裝

vial of 0.1 mL concentrate (240R-14)
vial of 0.5 mL concentrate (240R-15)
bottle of 1.0 mL predilute (240R-17)
vial of 1.0 mL concentrate (240R-16)
bottle of 7.0 mL predilute (240R-18)

製造商/商標名

Cell Marque

技術

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

同型

IgG

控制

colon carcinoma

運輸包裝

wet ice

儲存溫度

2-8°C

視覺化

cytoplasmic

基因資訊

human ... PTGS2(5743)

一般說明

Cyclooxygenase 2 (COX-2) catalyzes the conversion of arachidonic acid to prostaglandin H2 in the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. COX-2 inhibition by nonsteroidal anti-inflammatory agents has been shown to decrease angiogenesis and tumor growth, and promote apoptosis. COX-2 overexpression has been associated with increased microvascular density.

品質


IVD

IVD

IVD

RUO

聯結

COX-2 Positive Control Slides, Product No. 240S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

外觀

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

準備報告

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

其他說明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律資訊

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

H Sano et al.
Cancer research, 55(17), 3785-3789 (1995-09-01)
Several studies indicate that nonsteroidal anti-inflammatory drugs including indomethacin, aspirin, sulindac, and piroxicam reduce the risk of colon cancer. Furthermore, nonsteroidal anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme were shown to inhibit the development of colon cancer in animal
Oreste Gallo et al.
Human pathology, 33(7), 708-714 (2002-08-28)
Prostaglandins play a critical role in tumor development and growth by regulating numerous biologic processes, including tumor angiogenesis, with clear prognostic and therapeutic implications. The aim of this study was to investigate the prognostic relevance of cyclooxygenase-2 (COX-2) pathway activation
Jan Stoehlmacher et al.
Seminars in oncology, 30(3 Suppl 6), 10-16 (2003-06-13)
Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務